Company
Headquarters: Chengdu, China
Employees: 1,010
CN¥10.72 Billion
CNY as of Jan. 1, 2026
US$1.53 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry , and urinary system therapeutic categories. The company was founded in 2009 and is based in Chengdu, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥1.33 B |
| EBITDA | CN¥237.2 M |
| Gross Profit TTM | CN¥969.4 M |
| Profit Margin | 18.16% |
| Operating Margin | 21.91% |
| Quarterly Revenue Growth | -1.50% |
Chengdu Easton Biopharmaceuticals Co. Ltd has the following listings and related stock indices.
Stock: SSE: 688513 wb_incandescent